Get started

Financials · IGC

IGC Pharma Inc. (IGC) financials

For the twelve months ended Sep 30, 2026, IGC Pharma Inc. reported $1.26M of revenue and -$8.11M of net income.

Revenue, TTM
$1.26M
Revenue growth, YoY
+13.9%
Net income, TTM
-$8.11M
Net margin
-643.7%
Cash
$377.0K
P/S
18.08
Market cap
$22.8M
Annual revenue$1.27M
FY2016FY2025
Annual net income-$7.12M
FY2016FY2025
Annual free cash flow-$4.91M
FY2016FY2025

IGC revenue and earnings growth

IGC revenueQ2 2027$328.0K

Quarter YoY
+71.7%
QoQ
+23.8%
FY YoY
-5.5%
5Y CAGR
-20.8%
10Y CAGR
-16.5%

IGC revenue was $328.0K in fiscal Q2 2027 (ended Sep 30, 2026), up 71.7% from a year earlier and up 23.8% from the prior quarter. For the full fiscal 2025 it was $1.27M, down 5.5% from fiscal 2024. Compound annual growth was -20.8% over 5 years and -16.5% over 10 years. It rose in 4 of the last 10 fiscal years.

IGC net incomeQ2 2027-$2.05M

IGC net income was -$2.05M in fiscal Q2 2027 (ended Sep 30, 2026), compared with -$1.82M a year earlier. For the full fiscal 2025 it was -$7.12M, compared with -$13.00M in fiscal 2024.

IGC EPSQ2 2027-$0.02

IGC diluted EPS was -$0.02 in fiscal Q2 2027 (ended Sep 30, 2026), compared with -$0.02 a year earlier. For the full fiscal 2025 it was -$0.09, compared with -$0.22 in fiscal 2024.

IGC free cash flowQ4 2026-$1.22M

IGC free cash flow was -$1.22M in fiscal Q4 2026 (ended Mar 31, 2026), compared with -$748.0K a year earlier. For the full fiscal 2025 it was -$4.91M, compared with -$5.34M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Mar 31, 2025
FY2024
Mar 31, 2024
FY2023
Mar 31, 2023
FY2022
Mar 31, 2022
FY2021
Mar 31, 2021
FY2020
Mar 31, 2020
FY2019
Mar 31, 2019
FY2018
Mar 31, 2018
FY2017
Mar 31, 2017
FY2016
Mar 31, 2016
Revenue$1.27M$1.34M$911.0K$397.0K$898.0K$4.07M$5.12M$2.19M$580.4K$6.37M
Cost of revenue$652.0K$612.0K$469.0K$203.0K$785.0K$3.96M$4.98M$2.11M$362.1K$5.52M
Gross profit$619.0K$733.0K$442.0K$194.0K$113.0K$115.0K$132.0K$82.0K$218.2K$843.3K
Research and development$3.65M$3.77M$3.46M$2.33M$929.0K$1.01M$1.26M$137.0K--
Selling, general and admin$4.41M$6.76M$8.55M$13.29M$7.91M$5.97M$3.52M$1.73M$2.27M$2.70M
Operating income-$7.45M-$9.80M-$11.57M-$15.43M-$8.72M-$6.86M-$4.64M-$1.79M-$2.05M-$2.91M
Interest expense-------$30.7K$223.5K$213.9K
Pre-tax income-$7.12M-$13.00M-$11.51M-$15.02M-$8.81M-$7.32M-$4.09M-$1.79M-$1.84M-$2.83M
Income tax$0$0$0$0$0$0$2.0K$0$14.4K$579
Net income-$7.12M-$13.00M-$11.51M-$15.02M-$8.81M-$7.32M-$4.10M-$1.79M-$1.87M-$2.81M
EPS, basic-$0.09-$0.22---$0.21-$0.19-$0.13-$0.06-$0.07-$0.17
EPS, diluted-$0.09-$0.22---$0.21-$0.19-$0.13-$0.06-$0.07-$0.17
Diluted shares76.5M58.8M--42.0M39.5M35,39327,93725.7M16.4M

Balance sheet

Balance sheet
Line item
FY2025
Mar 31, 2025
FY2024
Mar 31, 2024
FY2023
Mar 31, 2023
FY2022
Mar 31, 2022
FY2021
Mar 31, 2021
FY2020
Mar 31, 2020
FY2019
Mar 31, 2019
FY2018
Mar 31, 2018
FY2017
Mar 31, 2017
FY2016
Mar 31, 2016
Cash and equivalents$405.0K$1.20M$3.20M$10.46M$14.55M$7.26M$25.61M$1.66M$538.0K$1.49M
Short-term investments$0$0$154.0K$0$80.0K$0$0$148.0K$1.88M$0
Receivables$34.0K$39.0K$107.0K$125.0K$175.0K$133.0K$84.0K$558.0K$752.9K$962.7K
Inventory$1.36M$1.54M$2.65M$3.55M$5.48M$4.25M$248.0K$486.0K$0$162.1K
Current assets$2.90M$3.71M$6.47M$15.11M$23.52M$17.76M$26.72M$3.21M$3.58M$3.84M
Goodwill-------$0$198.2K$1.18M
Total assets$8.75M$9.90M$17.18M$26.83M$35.87M$28.98M$34.47M$10.85M$11.28M$18.86M
Current liabilities$2.26M$2.34M$1.90M$2.44M$2.37M$1.95M$878.0K$2.35M$1.29M$3.20M
Short-term debt$3.0K$3.0K$3.0K$3.0K$304.0K$50.0K$50.0K$0$0$27.8K
Long-term debt$134.0K$137.0K$141.0K$144.0K$276.0K$0--$452.1K$801.5K
Total debt$137.0K$140.0K$144.0K$147.0K$580.0K$50.0K--$452.1K$829.2K
Total liabilities$2.42M$2.58M$2.27M$2.94M$3.06M$2.45M$893.0K$2.79M$3.93M$4.91M
Shareholders' equity$6.33M$7.32M$14.91M$23.89M$32.80M$26.54M$33.57M$8.06M$7.35M$13.95M

Cash flow

Cash flow
Line item
FY2025
Mar 31, 2025
FY2024
Mar 31, 2024
FY2023
Mar 31, 2023
FY2022
Mar 31, 2022
FY2021
Mar 31, 2021
FY2020
Mar 31, 2020
FY2019
Mar 31, 2019
FY2018
Mar 31, 2018
FY2017
Mar 31, 2017
FY2016
Mar 31, 2016
Operating cash flow-$4.79M-$5.20M-$7.05M-$7.46M-$10.80M-$8.68M-$3.33M-$1.93M-$1.39M-$157.7K
Capital expenditures$112.0K$138.0K$310.0K$236.0K$1.47M$4.39M$15.0K$136.0K$145.7K$122.2K
Free cash flow-$4.91M-$5.34M-$7.36M-$7.70M-$12.27M-$13.07M-$3.35M-$2.07M-$1.54M-$279.9K
Investing cash flow-$442.0K-$317.0K-$235.0K-$742.0K$3.39M-$9.55M-$260.0K-$657.0K-$241.4K-$183.4K
Financing cash flow$4.45M$3.52M$100.0K$4.14M$14.69M-$59.0K$27.60M$3.71M$707.6K$1.01M
Stock-based compensation$4.30M$4.60M$5.50M$7.00M$703.0K$521.0K$515.0K$576.3K$250.6K$214.3K
Depreciation and amortization$618.0K$637.0K$657.0K$651.0K$478.0K$144.0K$59.0K$19.0K$396.3K$728.7K

Key ratios

Key ratios
Line item
FY2025
Mar 31, 2025
FY2024
Mar 31, 2024
FY2023
Mar 31, 2023
FY2022
Mar 31, 2022
FY2021
Mar 31, 2021
FY2020
Mar 31, 2020
FY2019
Mar 31, 2019
FY2018
Mar 31, 2018
FY2017
Mar 31, 2017
FY2016
Mar 31, 2016
Revenue growth, YoY-5.5%47.6%129.5%-55.8%-77.9%-20.4%133.3%277.9%-90.9%-17.1%
Gross margin48.7%54.5%48.5%48.9%12.6%2.8%2.6%3.7%37.6%13.2%
Operating margin-585.8%-728.5%-1270.1%-3886.1%-971.5%-168.6%-90.8%-81.6%-354.0%-45.6%
Net margin-560.3%-966.5%-1263.0%-3782.4%-981.2%-179.6%-80.1%-81.4%-321.7%-44.1%
Free cash flow margin-386.1%-396.8%-807.6%-1939.0%-1366.4%-320.9%-65.4%-94.3%-264.8%-4.4%
Return on equity-112.5%-177.6%-77.2%-62.8%-26.9%-27.6%-12.2%-22.1%-25.4%-20.1%
Return on assets-81.4%-131.3%-67.0%-56.0%-24.6%-25.2%-11.9%-16.5%-16.5%-14.9%
Current ratio1.281.583.416.199.939.1230.441.372.781.20
Debt to equity0.020.020.010.010.020.00--0.060.06

Source: XBRL data IGC Pharma Inc. files with the SEC, latest filing dated Nov 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Jul 16, 2013.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

IGC peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
IGC$1.26M+13.9%-$8.11M-643.7%$22.8M
LLY$86.46B+45.5%$27.58B31.9%$1.35T
JNJ$99.33B+7.8%$16.09B16.2%$675.92B
ABBV$66.01B+10.7%$10.34B15.7%$519.48B
MRK$67.38B+4.9%$2.45B3.6%$364.98B
NVS$54.53B+8.4%$13.98B25.6%$311.52B
AZN$58.74B+8.6%$10.22B17.4%$289.61B
ABT$48.23B+10.0%$4.70B9.7%$191.31B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$180.22B

IGC FAQ

7 questions
  • What is IGC revenue?
    IGC Pharma Inc. (IGC) reported $1.26M of revenue for the twelve months ended Sep 30, 2026. That is up 13.9% from the year before. Revenue for fiscal 2025 was $1.27M.
  • Is IGC profitable?
    No. IGC Pharma Inc. reported a net loss of $8.11M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does IGC have?
    IGC Pharma Inc. reported $377.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is IGC revenue growing?
    IGC Pharma Inc.'s revenue changed -5.5% in fiscal 2025, to $1.27M. Its compound annual growth rate was -20.8% over 5 years and -16.5% over 10 years.
  • What is IGC gross margin?
    IGC Pharma Inc.'s gross profit was $208.0K on $1.26M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 16.5%.
  • When did IGC last report financial results?
    The latest statements here come from IGC Pharma Inc.'s 10-Q filed on Nov 6, 2026, covering the period ended Sep 30, 2026.
  • Where does this IGC financial data come from?
    Quantisnow builds these statements from the structured XBRL data IGC Pharma Inc. files with the SEC. It is provided for information only and is not investment advice.